Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
phage cocktail-SPK
- Development stage
- Phase 1
- Lead developer
- PrecisioBiotix
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Topical
01
Overview
Phage cocktail-SPK is a topical mixture of bacteriophages (viruses that specifically infect bacteria), designed as an adjunct treatment to standard care for wound infections. This phage cocktail targets several clinically significant pathogens—*Staphylococcus aureus*, *Pseudomonas aeruginosa*, and *Klebsiella pneumoniae*—with the primary intention of preventing or reducing these bacteria in wound settings, notably in burn wounds. Bacteriophages act by binding to bacterial cell surfaces, injecting their genetic material, and lysing (destroying) the bacteria through the lytic life cycle. This modality is being explored as an alternative or adjunct to antibiotics, especially against multidrug-resistant bacteria. The intervention is currently under clinical investigation for its safety, tolerability, and efficacy in reducing wound colonization and improving wound healing outcomes[5].
- Brand names
- phage cocktail-SPK
- Other names
- phage cocktail-SPK
02
Targets
Klebsiella pneumoniae surface antigensSpA (Staphylococcal protein A)P. aeruginosa (Pseudomonas aeruginosa)
Beyond the preview
Go deeper on phage cocktail-SPK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on phage cocktail-SPK.